BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30711541)

  • 1. Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease.
    Schilling J; Broemer M; Atanassov I; Duernberger Y; Vorberg I; Dieterich C; Dagane A; Dittmar G; Wanker E; van Roon-Mom W; Winter J; Krauß S
    J Mol Biol; 2019 Apr; 431(9):1869-1877. PubMed ID: 30711541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
    Martí E
    Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S; Reardon HT; Yin K; Mosier C; Hook V
    J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
    J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.
    Gipson TA; Neueder A; Wexler NS; Bates GP; Housman D
    RNA Biol; 2013 Nov; 10(11):1647-52. PubMed ID: 24256709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Fresh Look at Huntingtin mRNA Processing in Huntington's Disease.
    Romo L; Mohn ES; Aronin N
    J Huntingtons Dis; 2018; 7(2):101-108. PubMed ID: 29865084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.
    Matthes F; Massari S; Bochicchio A; Schorpp K; Schilling J; Weber S; Offermann N; Desantis J; Wanker E; Carloni P; Hadian K; Tabarrini O; Rossetti G; Krauss S
    ACS Chem Neurosci; 2018 Jun; 9(6):1399-1408. PubMed ID: 29506378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
    Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
    ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Widespread dysregulation of mRNA splicing implicates RNA processing in the development and progression of Huntington's disease.
    Tano V; Utami KH; Yusof NABM; Bégin J; Tan WWL; Pouladi MA; Langley SR
    EBioMedicine; 2023 Aug; 94():104720. PubMed ID: 37481821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.
    Goold R; Flower M; Moss DH; Medway C; Wood-Kaczmar A; Andre R; Farshim P; Bates GP; Holmans P; Jones L; Tabrizi SJ
    Hum Mol Genet; 2019 Feb; 28(4):650-661. PubMed ID: 30358836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels.
    Shin A; Shin B; Shin JW; Kim KH; Atwal RS; Hope JM; Gillis T; Leszyk JD; Shaffer SA; Lee R; Kwak S; MacDonald ME; Gusella JF; Seong IS; Lee JM
    Hum Mol Genet; 2017 Apr; 26(7):1258-1267. PubMed ID: 28165127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients.
    Neueder A; Landles C; Ghosh R; Howland D; Myers RH; Faull RLM; Tabrizi SJ; Bates GP
    Sci Rep; 2017 May; 7(1):1307. PubMed ID: 28465506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule splicing modifiers with systemic HTT-lowering activity.
    Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
    Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Influence of TBP CAG/CAA Repeats in Conjunction with HTT CAG Repeats on Huntington's Disease Age at Onset in a Brazilian Sample.
    da Silva IDS; Apolinário TA; de Andrade Agostinho L; Paiva CLA
    J Mol Neurosci; 2022 May; 72(5):1116-1124. PubMed ID: 35275350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.